AstraZeneca : Alexion data at 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) showcase impact of C5 inhibition in NMOSD -October 11, 2023 at 02:21 am EDT

Alexion, AstraZeneca Rare Disease, will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,Japan ,Boston ,Japanese ,Christophe Hotermans ,Odense University Hospital ,Research In Multiple Sclerosis ,Astrazeneca ,Head Of Global Medical Affairs ,Nasdaq ,Alexion Pharmaceuticals Inc ,Meeting Of The European Committee For Treatment ,Americas Committee For Treatment ,Astrazeneca Rare Disease ,Joint Meeting ,European Committee ,Multiple Sclerosis ,Americas Committee ,Senior Vice President ,Global Medical Affairs ,Five Best Poster Awards ,Alexion Pharmaceuticals ,Rare Diseases ,Markets ,